title: Pharmacokinetic implications for the clinical use of atropine, scopolamine and glycopyrrolate.
abstract: Several specific and sensitive new methods for determining atropine and its metabolites in biological fluids have increased the possibility to characterise the pharmacokinetic properties of this antimuscarinic agent. Following i.v. injection, atropine disappears very quickly from the circulation, resembling its fast onset of action. Age, but not sex, appears to have a clear effect on its kinetics, explaining at least partly the higher sensitivity of very young and very old patients to this anticholinergic agent. Following i.m. or oral atropine administration, typical anticholinergic effects coincide quite well with the absorption rate of the drug, indicating that the premedication should be given about 1 and 2 h before induction of anaesthesia. A sufficient absorption after rectal administration offers an alternative treatment, especially in children. Differing from its placental transfer, atropine has a delayed and incomplete lumbar cerebrospinal fluid penetration, indicating a fundamental difference between these two biological membranes. Oropharyngeally administered atropine has a very variable absorption, but inhaled or intratracheally given drug has produced interesting new results, e.g. pulmonary atropine administration appears to have clinical significance in special situations, such as cardiac arrest and organophosphate poisoning (military personnel). Depending on the method used, different data on the metabolism and excretion for atropine have been reported and therefore further studies are needed in this respect. The pharmacokinetics of scopolamine and glycopyrrolate and their relation to clinical response are poorly understood.
authors.affiliation: Department of Anaesthesiology, Turku University, Finland.
authors.forename: J
authors.initials: J
authors.lastname: Kanto
authors.forename: U
authors.initials: U
authors.lastname: Klotz
mesh_terms: D000375:Aging / Q000097:blood; D001285:Atropine / Q000008:administration & dosage* / Q000097:blood / Q000493:pharmacokinetics; D005260:Female; D006024:Glycopyrrolate / Q000097:blood / Q000493:pharmacokinetics; D006801:Humans; D010920:Placenta / Q000378:metabolism*; D011247:Pregnancy; D012601:Scopolamine / Q000097:blood / Q000134:cerebrospinal fluid / Q000493:pharmacokinetics
chemical_list: D001285:Atropine; D012601:Scopolamine; D006024:Glycopyrrolate